» Articles » PMID: 28818113

Respiratory Syncytial Virus (RSV) Entry is Inhibited by Serine Protease Inhibitor AEBSF when Present During an Early Stage of Infection

Overview
Journal Virol J
Publisher Biomed Central
Specialty Microbiology
Date 2017 Aug 19
PMID 28818113
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Host proteases have been shown to play important roles in many viral activities such as entry, uncoating, viral protein production and disease induction. Therefore, these cellular proteases are putative targets for the development of antivirals that inhibit their activity. Host proteases have been described to play essential roles in Ebola, HCV, HIV and influenza, such that specific protease inhibitors are able to reduce infection. RSV utilizes a host protease in its replication cycle but its potential as antiviral target is unknown. Therefore, we evaluated the effect of protease inhibitors on RSV infection.

Methods: To measure the sensitivity of RSV infection to protease inhibitors, cells were infected with RSV and incubated for 18 h in the presence or absence of the inhibitors. Cells were fixed, stained and studied using fluorescence microscopy.

Results: Several protease inhibitors, representing different classes of proteases (AEBSF, Pepstatin A, E-64, TPCK, PMSF and aprotinin), were tested for inhibitory effects on an RSV A2 infection of HEp-2 cells. Different treatment durations, ranging from 1 h prior to inoculation and continuing for 18 h during the assay, were evaluated. Of all the inhibitors tested, AEBSF and TPCK significantly decreased RSV infection. To ascertain that the observed effect of AEBSF was not a specific feature related to HEp-2 cells, A549 and BEAS-2B cells were also used. Similar to HEp-2, an almost complete block in the number of RSV infected cells after 18 h of incubation was observed and the effect was dose-dependent. To gain insight into the mechanism of this inhibition, AEBSF treatment was applied during different phases of an infection cycle (pre-, peri- and post-inoculation treatment). The results from these experiments indicate that AEBSF is mainly active during the early entry phase of RSV. The inhibitory effect was also observed with other RSV isolates A1998/3-2 and A2000/3-4, suggesting that this is a general feature of RSV.

Conclusion: RSV infection can be inhibited by broad serine protease inhibitors, AEBSF and TPCK. We confirmed that AEBSF inhibition is independent of the cell line used or RSV strain. The time point at which treatment with the inhibitor was most potent, was found to coincide with the expected moment of entry of the virion with the host cell.

Citing Articles

Influenza A virus propagation requires the activation of the unfolded protein response and the accumulation of insoluble protein aggregates.

Marques M, Ramos B, Albuquerque H, Pereira M, Ribeiro D, Nunes A iScience. 2024; 27(3):109100.

PMID: 38405606 PMC: 10884513. DOI: 10.1016/j.isci.2024.109100.


Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors: A Systematic Review.

Churiso G, Husen G, Bulbula D, Abebe L Infect Drug Resist. 2022; 15:7413-7430.

PMID: 36540102 PMC: 9759992. DOI: 10.2147/IDR.S387479.


Pharmacological Manipulation of UPR: Potential Antiviral Strategy Against Chikungunya Virus.

Agrawal N, Saini S, Khanna M, Dhawan G, Dhawan U Indian J Microbiol. 2022; 62(4):634-640.

PMID: 36458214 PMC: 9705628. DOI: 10.1007/s12088-022-01046-5.


Phage-Related Ribosomal Protease (Prp) of : In Vitro Michaelis-Menten Kinetics, Screening for Inhibitors, and Crystal Structure of a Covalent Inhibition Product Complex.

Hotinger J, Pendergrass H, Peterson D, Wright H, May A Biochemistry. 2022; 61(13):1323-1336.

PMID: 35731716 PMC: 9261936. DOI: 10.1021/acs.biochem.2c00010.


Purification of Antibodies From Human Milk and Infant Digestates for Viral Inhibition Assays.

Sah B, Lueangsakulthai J, Hauser B, Demers-Mathieu V, Scottoline B, Pastey M Front Nutr. 2020; 7:136.

PMID: 32984396 PMC: 7477105. DOI: 10.3389/fnut.2020.00136.


References
1.
Bolt G, Pedersen L, Birkeslund H . Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin. Virus Res. 2000; 68(1):25-33. DOI: 10.1016/s0168-1702(00)00149-0. View

2.
Welliver Sr R . The immune response to respiratory syncytial virus infection: friend or foe?. Clin Rev Allergy Immunol. 2007; 34(2):163-73. DOI: 10.1007/s12016-007-8033-2. View

3.
Meissner H . Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003; 22(2 Suppl):S40-4; discussion S44-5. DOI: 10.1097/01.inf.0000053884.21238.13. View

4.
Schepens B, Sedeyn K, Vande Ginste L, De Baets S, Schotsaert M, Roose K . Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. 2014; 6(11):1436-54. PMC: 4237470. DOI: 10.15252/emmm.201404005. View

5.
Collins P, Mottet G . Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol. 1991; 72 ( Pt 12):3095-101. DOI: 10.1099/0022-1317-72-12-3095. View